Who makes shu gan yi yang capsule simulation agent?

shu gan yi yang capsule simulation agent is developed by Beijing Hospital of Traditional Chinese Medicine.

What development phase is shu gan yi yang capsule simulation agent in?

shu gan yi yang capsule simulation agent is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

shu gan yi yang capsule simulation agent

Beijing Hospital of Traditional Chinese Medicine · FDA-approved active Small molecule Quality 0/100

Shu Gan Yi Yang Capsule Simulation Agent, marketed by Beijing Hospital of Traditional Chinese Medicine, holds a unique position in the traditional Chinese medicine segment. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market expansion.

At a glance

Generic name	shu gan yi yang capsule simulation agent
Sponsor	Beijing Hospital of Traditional Chinese Medicine
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial Scheme of Shu Gan yi Yang Capsule (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

shu gan yi yang capsule simulation agent CI brief — competitive landscape report
shu gan yi yang capsule simulation agent updates RSS · CI watch RSS
Beijing Hospital of Traditional Chinese Medicine portfolio CI